Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:16:36·⟳ 抓取 20:18:53 +2m17s·⚡ 决策 10-22 20:20:08 +1m15s·4.8 天前
吉利德将在AASLD 2026肝病年会展示Livdelzi与Hepcludex数据，但仅为会议前瞻、未披露新结果
跨源查重命中同一具体催化：2026-10-22 12:07 UTC已处理吉利德公司新闻稿版本，当前Investing.com文章仅为延迟转述，未新增疗效数值、审批状态或商业指引。
📄 原文Investing.com↗ 原文
Gilead to present liver disease data at AASLD meeting
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) announced it will present clinical and real-world data on tre…
不做 Gilead Sciences, Inc.（GILD.US）
同一AASLD会议前瞻已在13分钟前按公司新闻稿处理；当前Investing.com转述没有新增数据、审批、指引或订单事实，会议11月才召开，当前无正edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是AASLD会议数据展示前瞻，不是数据读出；21篇摘要、IDEAL III期和Hepcludex 96周数据均已在此前公司新闻稿事件中覆盖。当前没有可交易的新增事实，等待11月8日IDEAL正式结果。
🔎 新鲜度:最早出现 2026-10-22 · 扩散 low · price-in 风险 medium ↗
主要风险
- 真正的交易事件是11月8日IDEAL III期数据；若届时主要终点或临床获益验证不及预期，可能影响Livdelzi从加速批准转向完全批准的预期。
- 会议前瞻不等于临床结果，提前交易会同时承担数据失败、摘要细节不及预期和预期差不确定的风险。
先例如何影响了这次决策
对本次决策的影响:查重命中且无新增事实，直接AVOID；后续应把11月8日IDEAL正式数据作为新事件重新研究。
方向:不适用；本条在跨源查重阶段已确认是同一会议前瞻的重复转述，尚未进入需要用先例校准交易幅度的阶段。
涨幅量级:无ENTER标的且无新增事实，不设定止盈止损或涨幅预期。
形态:会议前瞻与实际数据读出是不同相位；不能用学术会议数据发布的历史反应替代当前无结果公告。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11,354 ms
{"result": "search_processed_events:agent query=`gilead aasld liver meeting 2026 abstracts livdelzi seladelpar ideal | gilead hepcludex bulevirtide 96-week data presentation november 2026 | 吉利德 肝病 数据 aasld 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26129 条本臂决策(完整)，返回 1 条候选。\n• 10-22 12:07 UTC(北京 20:0
原文全文
展开原文 · 1,925 字
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) announced it will present clinical and real-world data on treatments for primary biliary cholangitis and chronic hepatitis delta virus infection at The Liver Meeting 2026, according to a press release statement.
The company will present 21 abstracts at the American Association for the Study of Liver Diseases conference, scheduled for November 5-9 in Denver, Colorado.
For primary biliary cholangitis, Gilead will present Phase 3 results from the IDEAL study evaluating Livdelzi (seladelpar) 10 mg in adults with alkaline phosphatase levels between 1-1.67 times the upper limit of normal who were on or intolerant to ursodeoxycholic acid. Additional presentations will include safety and efficacy data for seladelpar treatment up to five years and data on fatigue.
For chronic hepatitis delta virus, the company will present 96-week efficacy findings on combined virologic and biochemical response with Hepcludex (bulevirtide-gmod), along with a 48-week analysis of portal hypertension prevalence and the drug’s impact in patients with chronic HDV.
Real-world studies will examine testing rates and disease burden in both conditions.
Livdelzi received accelerated approval in the United States for treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with inadequate response, or as monotherapy in patients unable to tolerate ursodeoxycholic acid. The approval was based on reduction of alkaline phosphatase, with continued approval contingent on verification of clinical benefit in confirmatory trials.
Hepcludex 8.5 mg received accelerated approval for treatment of chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis, based on decreased HDV RNA and ALT normalization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The company will present 21 abstracts at the American Association for the Study of Liver Diseases conference, scheduled for November 5-9 in Denver, Colorado.
For primary biliary cholangitis, Gilead will present Phase 3 results from the IDEAL study evaluating Livdelzi (seladelpar) 10 mg in adults with alkaline phosphatase levels between 1-1.67 times the upper limit of normal who were on or intolerant to ursodeoxycholic acid. Additional presentations will include safety and efficacy data for seladelpar treatment up to five years and data on fatigue.
For chronic hepatitis delta virus, the company will present 96-week efficacy findings on combined virologic and biochemical response with Hepcludex (bulevirtide-gmod), along with a 48-week analysis of portal hypertension prevalence and the drug’s impact in patients with chronic HDV.
Real-world studies will examine testing rates and disease burden in both conditions.
Livdelzi received accelerated approval in the United States for treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with inadequate response, or as monotherapy in patients unable to tolerate ursodeoxycholic acid. The approval was based on reduction of alkaline phosphatase, with continued approval contingent on verification of clinical benefit in confirmatory trials.
Hepcludex 8.5 mg received accelerated approval for treatment of chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis, based on decreased HDV RNA and ALT normalization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
21b01bd0e9· 2026-10-22 20:20 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前